

DAFTAR PUSTAKA

1. Global Cancer Observatory. The Global Cancer Observatory - All cancers. International Agency for Research on Cancer - WHO. 2020. hal. 1–2.
2. Global Cancer Observatory. Indonesia Cancer Fact Sheet. International Agency for Research on Cancer. 2020. hal. 1–2.
3. Roezin A, Adham M. Karsinoma Nasofaring. In: Soepardi EA, Iskandar N, Bashiruddin J, Restuti RD, editor. Buku Ajar Ilmu Kesehatan THT FK UI. 2007. hal. 182–7.
4. Utama DS. the Characteristics of Nasopharyngeal Carcinoma Patients in Moehammad Hoesin General Hospital Palembang January 2013 - December 2017. *Int J Nasopharyngeal Carcinoma*. 2019;1(1):30–2.
5. Global Cancer Observatory. Nasopharynx Fact Sheet. World Health Organization. 2020.
6. Ma J, Cao S. The Epidemiology of Nasopharyngeal Carcinoma. In: Lu JJ, Cooper JS, Lee AWM, editor. *Nasopharyngeal Cancer Multidisciplinary Management*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2010. hal. 1–7. (Medical Radiology).
7. Salehiniya H, Mohammadian M, Hashejani A, Mahdavifar N. Nasopharyngeal Cancer in the World: Epidemiology, Incidence, Mortality and Risk Factors. *World Cancer Res J*. 2018;5(1):1–8.
8. Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2021;30(6):1035–47.
9. Minorities E, Populations OU. AACR Cancer Disparities Progress Report 2022. In Philadelphia: American Association for Cancer Research; 2022. hal. 10.
10. Jodie RM, Rahman s, Aladin . Gambaran Terapi dan Respon Terapi Karsinoma Nasofaring di RSUP Dr. M. Djamil Padang. Vol. 1, *Jurnal Otorinolaringologi Kepala dan leher Indonesia*. 2021.
11. Bai R, Sun J, Xu Y, Sun Z, Zhao X. Incidence and mortality trends of nasopharynx cancer from 1990 to 2019 in China: an age-period-cohort analysis. *BMC Public Health*. 15 Desember 2022;22(1):1351.
12. Hardiati RH, Nabila C, Milenia UN. Klasifikasi, Faktor Risiko, Tatalaksana dan Komplikasi Kanker Nasofaring. *J Ilm Univ Batanghari Jambi*. 2022;22(1):304–7.
13. Faiza S, Rahman S, Asri A . Karakteristik Klinis dan Patologis Karsinoma Nasofaring di Bagian THT-KL RSUP Dr.M.Djamil Padang. *J Kesehat Andalas*. 2016;5(1):90–6.
14. Lo SS, Lu JJ. Natural History, Presenting Symptoms, and Diagnosis of Nasopharyngeal Carcinoma. In: Lu JJ, Cooper JS LA, editor. *Nasopharyngeal Cancer Multidisciplinary Management*. 2010. hal. 41–51.
15. Jiang L, Zhang C. Complete Response with Combined Therapy in a Patient with Brain Metastasis from Nasopharyngeal Carcinoma: Case Report and Literature Review. *J Int Med Res*. 2023;51(1):1–8.
16. Sinambela A. Revolusi Teknik Radioterapi pada Kanker Nasofaring. *Radioter Onkol Indones*. 2018;9(1):20–8.

17. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B , Gondhowiardjo S, Tan MJ. Nasopharyngeal Carcinoma in Indonesia: Epidemiology, Incidence, Signs, and Symptoms at Presentation. *Chin J Cancer*. 2012;31(4):185–96.
18. Yang Y, Shen C, Hu C. Effect of COVID-19 Epidemic on Delay of Diagnosis and Treatment Path for Patients with Nasopharyngeal Carcinoma. *Cancer Manag Res*. Mei 2020;Volume 12:3859–64.
19. Menteri Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/684/2019 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Nasofaring. In 2019. hal. 9–30.
20. Paiar F, Cataldo VD, Zei G, Pasquetti EM, Cecchini S, Meattini I, et al. Role of Chemotherapy in Nasopharyngeal Carcinoma. *Oncol Rev*. 12 Juni 2012;6(1):1.
21. Zeng MS, Zeng XY. Pathogenesis and Etiology of Nasopharyngeal Carcinoma. In: Lu JJ, Cooper JS LA, editor. *Nasopharyngeal Cancer Multidisciplinary Management*. 2010. hal. 9–25.
22. Jodie RM, Rahman S, Aladin. Gambaran Terapi dan Respon Terapi Karsinoma. 2021;1(1):20–7.
23. Nicholas L. Mankowski; Bruno Bordoni. *Anatomy, Head and Neck, Nasopharynx*. StatPearls. StatPearls Publishing, Treasure Island (FL); 2023.
24. Regauer S. Nasopharynx and Waldeyer's Ring. In: *Pathology of the Head and Neck*. Berlin/Heidelberg: Springer-Verlag; 2006. hal. 171–96.
25. PDQ Adult Treatment Editorial Board. *Nasopharyngeal Carcinoma Treatment: Health Professional Version*. PDQ Cancer Information Summaries; 2022.
26. Anthony L. Mescher. *Jonqueira's Basic Histology*. 13 TH. McGraw-Hill Education. 2018.
27. Usnam HA, Soehartono, Rahaju P. Histopatologi. In: Farhat, Adham M, Dewi YA, Indrasari SR, editor. *Karsinoma Nasofaring*. penerbit buku kedokteran EGC; 2020. hal. 29–38.
28. Yusmawan W, Antono D. Anatomi. In: Farhat, Adham M, Dewi YA IS, editor. *Karsinoma Nasofaring*. 2020. hal. 19–28.
29. Liem SK, Gunardi S KS. *sobotta edisi 24 volume 3*. In Elsevier; 2019.
30. Barnes L, Eveson JW, Reichart P, Sidransky D, editor. *Nasopharynx*. In: *World Health Organization Classification of Tumours*. 2019. hal. 81–106.
31. Tsao SW, Tsang CM, Lo KW. Epstein–Barr Virus Infection and Nasopharyngeal Carcinoma. *Philos Trans R Soc B Biol Sci*. 19 Oktober 2017;372.
32. Amanah NS. Faktor-Faktor Penyebab Terjadinya Karsinoma Nasofaring (KNF). *WELLNESS Heal Mag*. 2020;2(1):113–20.
33. N, Azizah, Hanriko R, Ramkita N . Hubungan antara Konsumsi Ikan Asin , Ikan / Daging Asap , dan Makanan Berkaleng dengan Karsinoma Nasofaring di RSUD Abdul Moeloek Periode Tahun 2014-2016 The Relation of Salted Fish , Smoked Fish / Beef , and Canned Food Consumption with Nasopharyngeal Ca. *J Kedokt Univ Lampung*. 2017;4(2):260–3.
34. Hsu WL, Chien YC, Huang YT, Yu KJ, Ko JY, Lin CY, et al. Cigarette Smoking Increases the Risk of Nasopharyngeal Carcinoma Through the

- Elevated Level of IgA Antibody Against Epstein-Barr Virus Capsid Antigen: A Mediation Analysis. *Cancer Med.* 2020;9(5):1867–76.
35. Xie SH, Yu ITS, Tse LA, Mang OWK, Yue L. Sex Difference in the Incidence of Nasopharyngeal Carcinoma in Hong Kong 1983-2008: Suggestion of a Potential Protective Role of Oestrogen. *Eur J Cancer.* 2013;49(1):150–5.
 36. Purwanto H. Hubungan Usia dan Jenis Kelamin dengan Kejadian Karsinoma Nasofaring Di RSUD Dr. H. Abdul Moeloek Provinsi Lampung Tahun 2013-2014. *J Med Malahayati.* 2015;2(3):146–50.
 37. Kuswandi A, Kuswandi NH, Kasim M, Tan'im T, Wulandari M. Karakteristik Histopatologi dan Stadium Klinis Kanker Nasofaring. *J Ilm Kesehat Sandi Husada.* 2020;11(1):243–51.
 38. Hibatullah H, Mohamad PB, Heriady Y. Karakteristik Penderita Karsinoma Nasofaring di Rumah Sakit Umum Daerah Al-Ihsan Bandung Periode 2017-2019. *Pros Pendidik Dr.* 2021;7(1):54–62.
 39. Aslam, Irawirawan H, Riasiti Y. Gambaran Penderita Karsinoma Nasofaring di RSUD Abdul Wahad Sjahranie Samarinda Periode 2016-2020. 2022;4(1):306–15.
 40. Zhang H, Wang J, Yu D, Liu Y, Xue K, Zhao X. Role of Epstein-Barr Virus in the Development of Nasopharyngeal Carcinoma. *Open Med.* 2017;12(1):171–6.
 41. Tao Q, Chan ATC. Nasopharyngeal Carcinoma: Molecular Pathogenesis and Therapeutic Developments. *Expert Rev Mol Med.* 2007;9(12):1–24.
 42. Kumar V, Abbas AK, Aster JC. Neoplasia. In: *Robbins Basic Pathology.* 9th ed. Philadelphia: Elsevier; 2015. hal. 161–2.
 43. Rizky MM, Imanto M. Peran Latent Membrane Protein (LMP) dan Micro RNA dalam Patogenesis Karsinoma Nasofaring yang Disebabkan oleh Virus Epstein-Barr. *Majority.* 2017;7(1):149.
 44. Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VMY, Zhang G, et al. Etiological Factors of Nasopharyngeal Carcinoma. *Oral Oncol.* Mei 2014;50(5):330–8.
 45. Faisal HH. Gambaran Karakteristik Karsinoma Nasofaring dan Faktor-Faktor yang Mempengaruhi Prognosis. *J Univ Indones.* 2016;1–24.
 46. Adham M, Lazim NM CR. Clinical Presentation of Nasopharyngeal Carcinoma. In: *An Evidence-Based Approach to the Management of Nasopharyngeal Cancer.* Elsevier; 2020. hal. 93–109.
 47. Sigarlaki ED, Imanto M, Cania E. Tatalaksana Radioterapi pada Karsinoma Nasofaring. *Medula.* 2019;8(2):23–6.
 48. Wicaksana AAGOS, Asthuta AR . Karakteristik Pasien Kanker Nasofaring di Poli THT- KL RSUP Sanglah Pada Tahun 2015. *E-Jurnal Med.* 2019;8(2).
 49. Khoo ASB, Pua KC. Diagnosis and Clinical Evaluation of Nasopharyngeal Carcinoma. *Adv Exp Med Biol.* 2013;778:1–9.
 50. Wei WI CD. Pharynx : Nasopharynx. In: *Stell & Maran's Textbook of Head and Neck Surgery and Oncology.* CRC Press; 2011. hal. 588–611.
 51. Primadina MA, Imanto M. Tumor Nasofaring dengan Diplopia Pada Pasien Usia 44 Tahun. *Medula.* 2017;7(4):181–6.
 52. Yousefi SH, Jimmy Ng AC. Eustachian Tube Dysfunction. *StatPearls Publishing, Treasure Island (FL);* 2023.

53. Teoh JW, Yunus RM, Hassan F, Ghazali N, Abidin ZAZ. Nasopharyngeal Carcinoma in Dermatomyositis Patients: A 10-Year Retrospective Review in Hospital Selayang, Malaysia. *Reports Pract Oncol Radiother*. September 2014;19(5):332–6.
54. Huang T, Zhang Z, Zhou X. Diagnosis and Therapy of Nasopharyngeal Carcinoma. In: *Pharynx - Diagnosis and Treatment*. IntechOpen; 2021.
55. Zhu QY, Zhao GX, Li Y, Talakatta G, Mai HQ, Le QT, et al. Advances in Pathogenesis and Precision Medicine for Nasopharyngeal Carcinoma. *MedComm*. 2021;2(2):175–206.
56. Putti TC TK. Pathology of Nasopharyngeal Carcinoma. In: *Nasopharyngeal Cancer Multidisciplinary Management*. 2010. hal. 71–80.
57. Ganeson SK, Saniasiaya J, Mohamad I GN. Basaloid Nasopharyngeal Carcinoma : Entity that Remains Oblivious. *Eur Univ Inst*. 2017;(2):2–5.
58. Shi Q, Shen C, Kong L, Wang X, Ding J, Gao Y, et al. Involvement of both Cervical Lymph Nodes and Retropharyngeal Lymph Nodes has prognostic value for N1 patients with Nasopharyngeal Carcinoma. *Radiat Oncol*. 2014;9(1):1–8.
59. Rahman S, Handayani T. Pemeriksaan Radiologi. In: Farhat, Adham M, Dewi YA IS, editor. *Karsinoma Nasofaring*. penerbit buku kedokteran EGC; 2020. hal. 107–14.
60. Ho FCH, Tham IWK, Earnest A, Lee KM, Lu JJ. Patterns of Regional Lymph Node Metastasis of Nasopharyngeal Carcinoma: A Meta-Analysis of Clinical Evidence. *BMC Cancer*. 2012;12.
61. Laksmi K, Wardhani WAK. Aliran Limfatik Daerah Kepala dan Leher serta Aspek Klinisnya. *J Ipa*. 2015;6:33–51.
62. Deschler DG, Moore MG, Smith RV. TNM Staging of Head and Neck Cancer and Neck Dissection Classification. In: *American Academy Otolaryngology - Head and neck surgery*. 2014. hal. 19–28.
63. Van DN, Nguyen TB, Thi NTN VQ. Report on Unusual Sites of Lymph Node Metastases in Nasopharyngeal Carcinoma. *Case Rep Oncol*. 2021;14(3):1821–6.
64. Qu W, Li S, Zhang M, Qiao Q. Pattern and Prognosis of Distant Metastases in Nasopharyngeal Carcinoma: A Large-Population Retrospective Analysis. *Cancer Med*. 2020;9(17):6147–58.
65. Shen L, Dong J, Li S, Wang Y, Dong A, Shu W, et al. M1 Stage Subdivision and Treatment Outcome of Patients With Bone-Only Metastasis of Nasopharyngeal Carcinoma. *Oncologist*. 2015;20(3):291–8.
66. Susilawati NK, Kadriyan H, Tengah KL. Bone Metastases in Nasopharyngeal Carcinoma. 2020;02(03):67–70.
67. Huang J, Li Q, Zheng Y, Shen J, Li B, Zou R, et al. Partial Hepatectomy for Liver Metastases from Nasopharyngeal Carcinoma: A Comparative Study and Review of the Literature. *BMC Cancer*. 2014;14(1):1–10.
68. Liu Q, Wang J, Sun C, Xu J. The Diagnosis and Management of Rare Cystic Liver Metastases from Nasopharyngeal Carcinoma. *Med (United States)*. 2018;97(26):1–5.
69. Zhao ZR, Liu DH, Wang YZ, Sun XS, Long H. Pulmonary Metastasectomy in Patients with Lung Metastases from Nasopharyngeal Carcinoma. *Ann Surg Oncol*. 2021;28(8):4542–50.

70. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge from a Population-based to a more “Personalized” Approach to Cancer Staging. *CA Cancer J Clin.* 2017;67(2):93–9.
71. American Joint Committee on Cancer. AJCC Cancer Staging Manual, Eighth Edition. In: American College of Surgeons; 2018. hal. 17–20.
72. Limkin EJ, Blanchard P. Does East meet West? Towards a Unified Vision of the Management of Nasopharyngeal Carcinoma. *Br J Radiol.* 2019;92(1102).
73. Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, et al. Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines. In: NCCN Guidelines. 2018. hal. 479–90.
74. Du T, Xiao J, Qiu Z, Wu K. The Effectiveness of Intensity-Modulated Radiation Therapy Versus 2D-RT for the Treatment of Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis. *PLoS One.* 2019;14(7):1–14.
75. Kentjono WA, Surarso B, Yusuf M RA. Kemoterapi. In: Farhat, Adham M, Dewi YA IS, editor. *Karsinoma Nasofaring*. penerbit buku kedokteran EGC; 2020. hal. 159–88.
76. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal Carcinoma. *Lancet.* 2019;394(10192):64–80.
77. Yusuf M. Faktor Prognostik Karsinoma Nasofaring terhadap Respon Terapi. In: *Paradigma dan Manajemen Terkini pada Kasus Onkologi THT-KL*. Airlangga University Press, 2022; 2022. hal. 77–9.
78. Soesono B, Wijaya FO. Deteksi Dini dan Diagnosis Karsinoma Nasofaring. *Cdk-254.* 2017;44(7):478–81.
79. Amin AM, Juniati D. Klasifikasi Kelompok Umur Manusia. *MATHunesa.* 2017;2(6):32–4.
80. Supartondo, Bambang Setiyohadi. Anamnesis. In: *Buku Ajar Ilmu Penyakit Dalam*. 2017. hal. 125–8.
81. Tresker S. A Typology of Clinical Conditions. *Stud Hist Philos Biol Biomed Sci.* 2020;1–9.
82. Claude L, Emmanuel J, Duvergé L OD. Nasopharyngeal carcinoma special feature : Review Article Update in pediatric nasopharyngeal undifferentiated carcinoma. *Br Inst Radiol.* 2019;92(July):1–10.
83. Farhat F, Daulay ER, Chrestella J, Asnir RA, Yudhistira A SR. Correlation of P38 mitogen-activated protein kinase expression to clinical stage in nasopharyngeal carcinoma. *Open Access Maced J Med Sci.* 2018;6(11):1982–5.
84. Prabowo I, Dewi YA, Farhat, Asnir AA, Yudhistira A SM. Faktor Risiko. In: *Karsinoma Nasofaring*. 2020. hal. 51–70.
85. Xiao G, Cao Y, Qiu X, Wang W, Wang Y. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. *BMC Cancer.* 2013;13(226):1–8.
86. Feng RM, Chang ET, Liu Z, Liu Q, Cai Y, Zhang Z, et al. Reproductive history and risk of nasopharyngeal carcinoma: A population-based case–control study in southern China. *Oral Oncol.* Januari 2019;88:102–8.
87. Susantini IGAD, Adiprayoga NR, Mahayana IBY FU. Gambaran klinis-

- histopatologi pasien karsinoma nasofaring di Rumah Sakit Umum Daerah (RSUD) Buleleng pada tahun 2021-Agustus 2023. 2023;14(3):1064–8.
88. Shoffi MN, Halim AS DW. Karakteristik Klinis Dan Histopatologi Karsinoma Nasofaring Di Rspal Dr. Ramelan, Surabaya. Surabaya Biomed J. 2021;1(1):31–8.
 89. Utomo AW, Romdhoni AC. Characteristics of patients with nasopharyngeal carcinoma in Dr. Soetomo General Academic Hospital Surabaya. Bali Med J. 2023;12(2):1589–93.
 90. Adham M, Rohdiana D, Mayangsari ID MZ. Delayed diagnosis of nasopharyngeal carcinoma in a patient with early signs of unilateral ear disorder. Med J Indones. 2014;23(1):52–7.
 91. Arohmah NK, Oyong PR. Gambaran Klinis dan Faktor Risiko Penderita Kanker Nasofaring Clinical Overview and Risk Factors for Nasopharyngeal Cancer. Conf Innov Heal Account Manag Sci. 2020;1(Vol. 1 (2020): Proceeding 1st Setia Budi Conference on Innovation in Health, Accounting, and Management Sciences 2020):205–10.
 92. Rafiq F, Rehman A KA. Clinical presentation of nasopharyngeal carcinoma - An experience at ENT Department, Jinnah Hospital, Lahore. Pakistan J Med Heal Sci. 2018;12(3):1103–5.
 93. Romdhoni AC, Alkaff FF, KahdinA M, Masturina M, Ramadhani S s. Clinical presentation of nasopharyngeal Carcinoma in East Java, Indonesia. Pakistan J Med Heal Sci. 2020;14(3):942–6.
 94. Dewi YA PA. Presentasi Klinis dan Diagnosis. In: Karsinoma Nasofaring. 2020. hal. 85–106.
 95. Jurniar, Setiani L S. Efektivitas kemoterapi yang berdampak pada peningkatan kualitas hiduppasien karsinoma nasofaring. J Kedokt Syiah Kuala. 2022;22(4):336–42.
 96. Zhang Y, Zhang ZC, Li WF, Liu X, Liu Q, Ma J. Prognosis and staging of parotid lymph node metastasis in nasopharyngeal carcinoma: An analysis in 10,126 patients. Oral Oncol. 2019;95(May):150–6.
 97. Xu Y, Huang T, Fan L, Jin W, Chen X CJ. Patterns and Prognostic Value of Lymph Node Metastasis on Distant Metastasis and Survival in Nasopharyngeal Carcinoma: A Surveillance, Epidemiology, and End Results Study, 2006-2015. J Oncol. 2019;2019:1–8.
 98. Ho FCH, Tham IWK, Earnest A, Lee KM LJ. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: A meta-analysis of clinical evidence. BMC Cancer. 2012;12:1–13.
 99. Reyani NN, Rahman S, Muhammad S. Hubungan Jumlah Trombosit dengan Stadium Karsinoma Nasofaring di RSUP Dr. M. Djamil Padang. J Ilmu Kesehat Indones. 2023;4(1):33–40.
 100. Li AC, Xiao WW, Shen GZ, Wang L, Xu AA, Cao YQ, Huang SM, Lin CG, Han F, Deng XW ZC. Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: Long-term results and benefits of chemotherapy. Oncotarget. 2015;6(27):24511–21.
 101. Yang X, Ren H, Yu W, Li H, Yang X FJ. Bone Metastases Pattern in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Real-World Analysis in the SEER Database. Biomed Res Int. 2020;2020:1–10.
 102. Yang L, Xia L, Wang Y, He S, Chen H, Liang S, Peng P, Hong S CY.

- Development and external validation of nomograms to predict the risk of skeletal metastasis at the time of diagnosis and skeletal metastasis-free survival in nasopharyngeal carcinoma. *BMC Cancer*. 2017;17(1):1–13.
103. Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, et al. NCCN guidelines ® insights: Head and neck cancers, version 1.2018 featured updates to the NCCN guidelines. *JNCCN J Natl Compr Cancer Netw*. 2018;16(5):479–90.
 104. Kentjono WA, Surarso B, Yusuf M RA. Kemoterapi. In: *Karsinoma Nasofaring*. 2020. hal. 159–87.
 105. Wang Q, Xu G, Xia Y, Zuo J, Zeng G, Xue Z, Cao R, Xiong W LW. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma. *Oral Oncol*. 2020;111(April):104925.

